LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation

查看全文 作　　者：Jian [1,2,6]Sun;Tongzhu [1,2]Jin;Zhihui [1,2]Niu;Jiayu [1,2]Guo;Yingying [1,2]Guo;Ruoxuan [1,2]Yang;Qianqian [1,2]Wang;Huiying [1,2]Gao;Yuhan [1,2]Zhang;Tianyu [1,2]Li;Wenxin [3]He;Zhixin [3]Li;Wenchao [1,2]Ma;Wei [1,2]Su;Liangliang [1,2]Li;Xingxing [4]Fan;Hongli [1,2,5]Shan;Haihai [1,2,5]Liang

机构地区：[1]Department of Pharmacology(State-Province Key Laboratories of Biomedicine-Pharmaceutics of China,Key Laboratory of Cardiovascular Research,Ministry of Education),College of Pharmacy,Harbin Medical University,Harbin 150081,China;[2]Northern Translational Medicine Research and Cooperation Center,Heilongjiang Academy of Medical Sciences,Harbin Medical University,Harbin 150081,China;[3]Department of Thoracic Surgery,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China;[4]State Key Laboratory of Quality Research in Chinese Medicine/Macao Institute for Applied Research in Medicine and Health,Macao University of Science and Technology,Macao(SAR),China;[5]Research Unit of Noninfectious Chronic Diseases in Frigid Zone(2019RU070),Chinese Academy of Medical Sciences,Harbin 150081,China;[6]Zhuhai People's Hospital,Guangdong Provincial Key Laboratory of Tumor Interventional Diagnosis and Treatment,Zhuhai Hospital Affiliated with Jinan University,Jinan University,Zhuhai 519000,China

出　　处：《Acta Pharmaceutica Sinica B》索引2022年第12卷第9期,共16页

基　　金：supported by the National Natural Science Foundation of China (32171127 and 91949109);the HMU Marshal Initiative Funding (HMUMIF-21023, China);the Major Scientific Fund Project of Heilongjiang Province (ZD2019H001, China);the CAMS Innovation Fund for Medical Sciences (CIFMS, 2019-I2M5-078, China);the Guangdong Province Basic and Applied Basic Research Fund (2021A1515111049, China);Postgraduate Research and Practice Innovation Program of HMU (YJSCX202015HYD, China) 摘　　要：Idiopathic pulmonary fibrosis(IPF)is a progressive disease with unknown etiology and limited therapeutic options.Activation of fibroblasts is a prominent feature of pulmonary fibrosis.Here we report that lncRNA DACH1(dachshund homolog 1)is downregulated in the lungs of IPF patients and in an experimental mouse model of lung fibrosis.LncDACH1 knockout mice develop spontaneous pulmonary fibrosis,whereas overexpression of LncDACH1 attenuated TGF-β1-induced aberrant activation,collagen deposition and differentiation of mouse lung fibroblasts.Similarly,forced expression of LncDACH1 not only prevented bleomycin(BLM)-induced lung fibrosis,but also reversed established lung fibrosis in a BLM model.Mechanistically,LncDACH1 binding to the serine/arginine-rich splicing factor 1(SRSF1)protein decreases its activity and inhibits the accumulation of Ctnnb1.Enhanced expression of SRSF1 blocked the anti-fibrotic effect of LncDACH1 in lung fibroblasts.Furthermore,loss of LncDACH1 promoted proliferation,differentiation,and extracellular matrix(ECM)deposition in mouse lung fibroblasts,whereas such effects were abolished by silencing of Ctnnb1.In addition,a conserved fragment of LncDACH1 alleviated hyperproliferation,ECM deposition and differentiation of MRC-5 cells driven by TGF-β1.Collectively,LncDACH1 inhibits lung fibrosis by interacting with SRSF1 to suppress CTNNB1 accumulation,suggesting that LncDACH1 might be a potential therapeutic target for pulmonary fibrosis. 关键词：Idiopathic pulmonary fibrosis LncRNA DACH1 SRSF1 CTNNB1 FIBROBLAST MYOFIBROBLAST Extracellular matrix Proliferation

相关文献

参考文献（35）
引证文献（3）
耦合文献（203）

参考文献(35)

引证文献(3)

耦合文献(203)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

LncRNA DACH1 protects against pulmonary fibrosis by binding to SRSF1 to suppress CTNNB1 accumulation

参考文献(35)

引证文献(3)

耦合文献(203)

用户提示